Skip to main content


Showing posts from May, 2017

Post-doctoral positions

Two exciting post-doctoral projects are available via the ESPOD and EBPOD schemes between the European Bioinformatics Institute and respectively the Sanger Institute and the NIHR Cambridge Biomedical Research Centre (BRC). Post-doctoral fellows appointed via these schemes work on projects under the joint supervision of faculty members from EMBL-EBI and the Sanger or BRC as appropriate. Specifically: (a) In collaboration with Mathew Garnet at the Sanger Institute, a project to exploit the potential of combining large-scale drug sensitivity screening platforms with the chemogenomics resources and expertise at the EBI. A full description of the project can be found here: . Applications can be made via the relevant link here: (b) In collaboration with Vasilis Kosmoliaptsis in the Department of Surgery at Addenbrooke’s hospital, to c

ChEMBL_23 released

We are pleased to announce the release of ChEMBL_23. This release was prepared on 1st May 2017 and contains: * 2,101,843 compound records * 1,735,442 compounds (of which 1,727,112 have mol files) * 14,675,320 activities * 1,302,147 assays * 11,538 targets * 67,722 source documents Data can be downloaded from the ChEMBL ftp site: Please see ChEMBL_23 release notes for full details of all changes in this release: DATA CHANGES SINCE THE LAST RELEASE In addition to the regular updates to the Scientific Literature, FDA Orange Book and USP Dictionary of USAN and INN Investigational Drug Names and Clinical Candidates, this release of ChEMBL also includes the following new data: Patent Bioactivity Data With funding from the NIH Illuminating the Druggable Genome project (https://commonf